-
Praeruptorin A, DMT1, and Ferroptosis in DIC
2026-09-05
This study used a ferrous ion probe to screen herbal small molecules and identified Praeruptorin A as an inhibitor of DMT1-associated iron overload and ferroptosis in doxorubicin-induced cardiomyopathy. Cellular and mouse experiments indicate that Praeruptorin A can protect cardiac function while retaining, and potentially complementing, doxorubicin’s antitumor activity.
-
WSP-5 for Live-Cell H2S Imaging
2026-09-04
WSP-5 combines reaction-based selectivity with rapid turn-on fluorescence for tracking hydrogen sulfide in living cells, donor-release assays, and disease models. This practical guide connects the probe to diabetic cardiomyopathy research while emphasizing controls, dosing decisions, and troubleshooting for reproducible imaging.
-
Separating Growth Arrest from Cell Death in Cancer Assays
2026-09-04
Hannah Schwartz’s dissertation shows why relative viability and fractional viability should not be treated as interchangeable measures of anticancer activity. By separating proliferative arrest from cell killing and considering their timing, the work offers a more informative framework for interpreting drug responses, including studies of histone deacetylase inhibitors.
-
Okadaic acid (A4540): PP1/PP2A Workflow
2026-09-03
Okadaic acid (A4540) provides a controlled way to inhibit PP2A-dominant or combined PP1/PP2A serine/threonine phosphatase activity in biochemical, signaling, and apoptosis workflows. It should be used with vehicle, concentration, density, and endpoint controls rather than treating biochemical IC50 values as universal cell-treatment doses.
-
3D Gold Nanocluster Arrays for Reproducible SERS
2026-09-03
Li and co-workers report a polymer pen lithography strategy for constructing ordered three-dimensional gold nanoparticle cluster arrays with tunable architectures. The substrates combine strong SERS enhancement with an intersubstrate reproducibility metric below 4.73%, highlighting structural regulation as a practical route to more reliable plasmonic sensing platforms.
-
M344 Histone Deacetylase Inhibitor Guide
2026-09-02
M344 is a cell-permeable histone deacetylase inhibitor that increases histone acetylation and suppresses growth in several cancer-cell models. Its strongest use is as an in vitro and ex vivo research tool for chromatin regulation, cell differentiation induction, radiation-response studies, and HIV-1 latency research.
-
Phenothiazines, ROS, and Macrophage Antibacterial Defense
2026-09-02
Qiu et al. show that phenothiazines strengthen macrophage control of intracellular bacteria through coordinated increases in lysosomal activity, reactive oxygen species, and autophagy. Pharmacological inhibition of autophagy or ROS weakened this effect, while perphenazine reduced lesion and inflammation outcomes in a Salmonella Typhimurium model, supporting phenothiazines as host-directed therapy leads.
-
HyperScribe T7 High Yield Cy3 RNA Labeling Kit Plus
2026-09-01
The HyperScribe™ T7 High Yield Cy3 RNA Labeling Kit Plus provides a defined in vitro transcription workflow for producing randomly Cy3-modified RNA probes for fluorescence-based detection. It is intended for research applications such as in situ hybridization and Northern blot hybridization, not for diagnostic, therapeutic, or medical use.
-
FAISL Stabilizes FAK in Triple-Negative Breast Cancer
2026-09-01
The reference study identifies FAISL as a focal adhesion kinase-interacting lncRNA that promotes triple-negative breast cancer by preventing Calpain 2-mediated FAK proteolysis. Its combination of transcriptomic discovery, mechanistic validation, and reduction-responsive nanoparticle delivery provides a framework for studying post-translational control of adhesion signaling and metastasis.
-
Promethazine HCl: Designing Better Immune Assays
2026-08-31
Promethazine HCl is more than an H1 antagonist: it can help researchers separate histaminergic signaling from ROS, lysosomal, and autophagy-dependent immune phenotypes. This guide translates recent macrophage findings into rigorous assay-design decisions.
-
Romidepsin (FK228) in HCC Research Workflows
2026-08-30
Romidepsin (FK228) gives researchers a practical way to connect class I HDAC inhibition with chromatin remodeling, spliceosome regulation, and DNA-repair vulnerability in hepatocellular carcinoma models. This workflow shows how to optimize exposure, verify target engagement, and evaluate combination responses with PARP inhibition without confusing enzyme potency with cell-based efficacy.
-
DAPI in PAD4-NETs Assay Design
2026-08-29
DAPI and 4',6-Diamidino-2-Phenylindole can do more than label nuclei. This guide explains how to use DAPI as a spatial and membrane-integrity checkpoint when investigating PAD4–H3cit–NETs biology, while avoiding overinterpretation of fluorescence alone.
-
8-Chloroadenosine for RNA Research Workflows
2026-08-29
Use 8-Chloroadenosine as a controlled RNA synthesis perturbation for transcriptional regulation research, RNA turnover experiments, and cancer cell assays. This workflow emphasizes DMSO-based preparation, time-resolved sampling, orthogonal decay controls, and interpretation safeguards that distinguish transcriptional effects from nonspecific cytotoxicity.
-
METTL16–SENP3–LTF Axis Drives HCC Ferroptosis Resistance
2026-08-28
Wang et al. identify a METTL16–SENP3–LTF signaling axis that protects hepatocellular carcinoma cells from iron-dependent lipid peroxidation and promotes tumor progression. The study connects m6A-dependent RNA regulation with SENP3-mediated protein stabilization and LTF-dependent iron sequestration, providing a mechanistic framework for sensitizing HCC to ferroptosis.
-
AMG 487 and the Contextual Logic of CXCR3
2026-08-28
A translational analysis of AMG 487 as a CXCR3 antagonist, using the CXCL10–CXCR3–LAMP1 axis to connect receptor pharmacology with macrophage state, inflammation, assay design, and preclinical decision-making.